ライフサイエンスコーパス: human leukocyte antigen

1 tocompatibility complex (MHC) class I genes (human leukocyte antigen A [HLA-A], -B, and -C genes) may

2 egion Y)-box 30 activated naive T cells from human leukocyte antigen A*02:01-positive human donors.

3 All patients' results were positive for human leukocyte antigen-A29.

4 No donor-specific human leukocyte antigen Abs or rejection episodes were n

5 tion studies have revealed associations with human leukocyte antigen and non-human leukocyte antigen

6 ssociation between HIV genetic variation and human leukocyte antigen and the other studying host rang

7 f-the-art technology employed to assess anti-human leukocyte antigen antibodies (Anti-HLA Ab) for don

8 Monitoring anti-human leukocyte antigen antibodies after cellular reject

9 Serologic determination of human leukocyte antigen antibodies showed higher positiv

10 liver, de novo detection of circulating anti-human leukocyte antigen antibodies, and clinically signi

11 nor age, human leukocyte antigen mismatches, human leukocyte antigen antibodies, cold ischemia time,

12 d Medicaid Services to evaluate whether anti-human leukocyte antigen antibodies, measured as panel re

13 nitial use of everolimus, and available anti-human leukocyte antigen antibody data.

14 ted with HIV/Mtb had decreased expression of human leukocyte antigen antigen D related and the costim

15 ytokine production and significantly reduced human leukocyte antigen - antigen D related expression.

16 e response to bacterial stimulation and less human leukocyte antigen - antigen D related.

17 d in peripheral blood mononuclear cells, and human leukocyte antigen-antigen D related expression on

18 hogenesis of DHRs with the identification of human leukocyte antigens as predisposing factors.

19 atic T-cell infiltrates and a strong genetic human leukocyte antigen association represent characteri

20 Human leukocyte antigen-B27 (HLA-B27)-positive acute ant

21 Human leukocyte antigen-B40 group and HLA-B8 were identi

22 ed using the highly sensitive single-antigen human leukocyte antigen bead assay 5.1 +/- 3.9 months af

23 sed strategy relies on initial prediction of human leukocyte antigen-binding peptides by in silico al

24 However, we identified in one patient a human leukocyte antigen-C*08:02-restricted T cell recept

25 patients, we observed reduced expression of human leukocyte antigen class DR (HLA-DR) and proinflamm

26 Human leukocyte antigen class I (HLA)-restricted CD8(+)

27 /= 40 years, adjusted P = 0.010) and several human leukocyte antigen class I (HLA-I) alleles, includi

28 nctional diversity of the highly polymorphic human leukocyte antigen class I (HLA-I) genes underlies

29 Human leukocyte antigen class I (HLA-I) molecules are en

30 efficient presentation of tumor antigens by human leukocyte antigen class I (HLA-I) molecules.

31 oglobulin-like receptors (KIRs) that bind to human leukocyte antigen class I (HLA-I).

32 h-throughput 13-parameter flow cytometry and human leukocyte antigen class I cytomegalovirus-specific

33 Invading placental trophoblast cells express human leukocyte antigen class I ligands (HLA-E, HLA-G, a

34 Analysis of immune responses ex vivo used human leukocyte antigen class I pentamers, intracellular

35 c flow cytometry with ultrasensitive peptide-human leukocyte antigen class I tetramer staining to qua

36 action between the T-cell receptor (TCR) and human leukocyte antigen class II (HLA-II).

37 CD133, and c-Met and the immunologic markers human leukocyte antigen class II and programmed death li

38 igen antibodies showed higher positivity for human leukocyte antigen class II donor-specific antibodi

39 y history of type 1 diabetes and susceptible human leukocyte antigen class II genotypes.

40 edict the antigens that will be presented by human leukocyte antigen class II molecules (HLA-II), hin

41 e system through their interactions with the human leukocyte antigen complex, and neoantigen presence

42 further support the link between ASD and the human leukocyte antigen complex.

43 context of human leukocyte antigen (peptide-human leukocyte antigen complex; pHLA) molecules on tumo

44 Tumor-associated peptide-human leukocyte antigen complexes (pHLAs) represent the

45 tages of circulating activated CD4+ T cells (human leukocyte antigen-D related [HLA-DR]+CD38+CD4+) (f

46 ients' monocytes expressed reduced levels of human leukocyte antigen-D-related peptide and released l

47 Monocyte expression of human leukocyte antigen-D-related peptide, sol-tumor nec

48 ents compared to non-PSC controls, including human leukocyte antigen DM alpha chain and chemokine (C-

49 Human leukocyte antigen-DM (HLA-DM) is an integral compo

50 Anti-human leukocyte antigen donor-specific antibodies (DSAs)

51 ipient dyslipidemia (P=0.009), class II anti-human leukocyte antigen donor-specific antibodies (P=0.0

52 histocompatibility complex class II (MHC-II) human leukocyte antigen DR isotype (HLA-DR) is an essent

53 tiation 38 (CD38) and CD69 but low levels of human leukocyte antigen DR, CD80, and CD86 at baseline.

54 reas levels of macrophage-derived chemokine, human leukocyte antigen DR, CD80, and CD86 were increase

55 down-regulated macrophage-derived chemokine, human leukocyte antigen DR, CD86, and CD80 correlated po

56 regulatory T-cell frequency, activated CD38+Human Leukocyte Antigen - DR isotype (HLA-DR)+ CD4 and C

57 iling showed increased circulating activated human leukocyte antigen, DR isotype ([HLA-DR] positive)

58 n of the ocular surface inflammatory markers human leukocyte antigen-DR (HLA-DR) and intercellular ad

59 6, but both demonstrated increased levels of human leukocyte antigen-DR (HLA-DR) following IFN-gamma

60 hest doses, an apparent increase in monocyte human leukocyte antigen-DR expression (> 5,000 monoclona

61 nd 20 septic shock patients stratified using human leukocyte antigen-DR expression on monocytes (mHLA

62 ion of gadolinium 160 ((160)Gd)-labeled anti-human leukocyte antigen-DR isotope (HLA-DR) antibodies t

63 nts included receptor occupancy and monocyte human leukocyte antigen-DR levels.

64 We found a profound decrease in human leukocyte antigen-DR on Mo and DCs in burned patie

65 The expression of human leukocyte antigen-DR was determined on all DCs and

66 plex class II (MHC II) and instead expresses human leukocyte antigen DR1 (HLA-DR1).

67 ecognized in SARS-CoV- and MERS-CoV-infected human leukocyte antigen DR2 and DR3 transgenic mice, ind

68 mplex class II antigen was replaced with the human leukocyte antigen DR4 (HLA-DR4).

69 nic acid, which suppresses the expression of human leukocyte antigen E (HLA-E) in cancer cells, thus

70 patibility complex (MHC), a mouse homolog of human leukocyte antigen-E (HLA-E), inhibits antibody-med

71 PPCLs uniformly expressed class I human leukocyte antigen, epithelial cell adhesion molecu

72 ulated sidedness dependent differential hMSC human leukocyte antigen expression, angiogenic and infla

73 tricted T cells and frequently downregulated human leukocyte antigen expression.

74 ocompatibility complex (MHC) molecule HLA-F (human leukocyte antigen F) regulates the immune system i

75 mma), indoleamine 2,3 dioxygenase (IDO), and human leukocyte antigen G (HLA-G) was determined.

76 Human leukocyte antigen G (HLA-G), a nonclassic HLA clas

77 atural immune tolerance mechanism induced by human leukocyte antigen G (HLA-G), was investigated.

78 al immune tolerance mechanism induced by the human leukocyte antigen G (HLA-G).

79 ual member of the KIR family that recognizes human leukocyte antigen G and mediates NK-cell activatio

80 Expression of the non-classical human leukocyte antigen-G (HLA-G) promotes cancer progre

81 irects differentiation preferentially toward human leukocyte antigen-G(+) pcEVT, and that an intact H

82 or receptor(+) villous cytotrophoblasts into human leukocyte antigen-G(+) proximal column EVT (pcEVT)

83 Invading human leukocyte antigen-G+ (HLA-G+) extravillous trophob

84 terleukin-10 gene (IL10) T3575A), rs6457327 (human leukocyte antigen gene (HLA) class I), rs10484561

85 However, the functional relationship between human leukocyte antigen gene(s) and disease development

86 variants associated with DHRs are located in human leukocyte antigen genes and genes involved in drug

87 Several of the human leukocyte antigen genes at this locus, such as HLA

88 iations with human leukocyte antigen and non-human leukocyte antigen genes of 3 major histocompatibil

89 analyzed for disease-associated variants in human leukocyte antigen genes; results must be carefully

90 e in the child after adjustment for country, human leukocyte antigen genotype, family history of celi

91 ,208 Graves' disease controls), using direct human leukocyte antigen genotyping and SNP-based genome-

92 The present review describes the biology of human leukocyte antigen haplotype mismatched ("haploiden

93 l that preparing the cells from donors whose human leukocyte antigen-haplotype are homozygous.

94 The HLA-DRB1*01 allele of the human leukocyte antigen has been associated with acute c

95 VDSLFFL (ALY) is presented in the context of human leukocyte antigen HLA-A*02:01 molecules for recogn

96 The immunosuppressive human leukocyte antigens HLA-G and HLA-F are expressed o

97 high-risk stage III melanoma were grouped by human leukocyte antigen (HLA) -A2 status.

98 is under strong genetic control by class II human leukocyte antigen (HLA) allele combinations.

99 sical MHC (chr6: 29.6-33.1 Mb), imputing 216 human leukocyte antigen (HLA) alleles and 4 complement c

100 dentifies new associations between classical human leukocyte antigen (HLA) alleles and common immune-

101 efore searched for genetic associations with human leukocyte antigen (HLA) alleles and IFN-lambda3 ge

102 Specific human leukocyte antigen (HLA) alleles have been identifi

103 tly, we detected the involvement of the same human leukocyte antigen (HLA) alleles in both SCZ and MS

104 cleotide Polymorphisms (SNPs) and 38 imputed Human Leukocyte Antigen (HLA) alleles were analyzed thro

105 e impact of source partner HIV-1 RNA levels, human leukocyte antigen (HLA) alleles, and innate respon

106 enome-wide association study (GWAS), imputed human leukocyte antigen (HLA) alleles, exome array and c

107 sture disease, is associated with particular human leukocyte antigen (HLA) alleles.

108 vering a variety of tissues, cell types, and human leukocyte antigen (HLA) alleles.

109 We performed human leukocyte antigen (HLA) analysis in 25 nontumor an

110 and medically important regions such as the human leukocyte antigen (HLA) and killer cell immunoglob

111 De novo donor-specific human leukocyte antigen (HLA) antibodies (DSA) posttrans

112 h complications including the development of human leukocyte antigen (HLA) antibodies.

113 iovascular risk factors and circulating anti-human leukocyte antigen (HLA) antibodies.

114 tric kidney recipients monitored for de novo human leukocyte antigen (HLA) antibody (Ab) occurrence t

115 mine the incidence of de novo donor-specific human leukocyte antigen (HLA) antibody (dnDSA) during th

116 ineered single allele cells to identify anti-human leukocyte antigen (HLA) antibody cross-species rea

117 plicate to determine the titer of individual human leukocyte antigen (HLA) antibody specificities.

118 a from these cohorts to further fine map the human leukocyte antigen (HLA) association and replicated

119 10(-9)) and confirm the previously reported human leukocyte antigen (HLA) associations on chromosome

120 xemplified by several key examples and their human leukocyte antigen (HLA) associations: abacavir and

121 for recurrence was higher for patients with human leukocyte antigen (HLA) B49 (odds ratio, 16.9; 95%

122 Efforts to precisely identify tumor human leukocyte antigen (HLA) bound peptides capable of

123 , a nonamer and a decamer, all restricted by human leukocyte antigen (HLA) C*08:02.

124 Despite the progress in human leukocyte antigen (HLA) causal variant mapping, in

125 The human leukocyte antigen (HLA) class I allele, HLA-C*06:0

126 While the relationship of protective human leukocyte antigen (HLA) class I alleles and HIV pr

127 pe and the Middle East, sequenced HDV, typed human leukocyte antigen (HLA) class I alleles from patie

128 requency in epitopes presented by protective human leukocyte antigen (HLA) class I alleles.

129 Human leukocyte antigen (HLA) class I allotypes vary in

130 Polymorphisms in the human leukocyte antigen (HLA) class I genes can cause th

131 patients with chronic HBV infection, and the human leukocyte antigen (HLA) class I genotype (A and B

132 In all human cells, human leukocyte antigen (HLA) class I glycoproteins asse

133 Nef clone's ability to downregulate CD4 and human leukocyte antigen (HLA) class I in vitro We then e

134 Possession of the human leukocyte antigen (HLA) class I molecule B27 is st

135 ented on tumors and not on normal tissues by human leukocyte antigen (HLA) class I molecules are prom

136 Major Histocompatibility Complex (MHC) or Human Leukocyte Antigen (HLA) Class I molecules bind to

137 Micropolymorphisms within human leukocyte antigen (HLA) class I molecules can chan

138 Human leukocyte antigen (HLA) class I molecules generall

139 Peptides were eluted from human leukocyte antigen (HLA) class I molecules of MuV-i

140 oteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules that eli

141 ion of several LRC products with polymorphic human leukocyte antigen (HLA) class I molecules.

142 lved two broad strategies for recognition of human leukocyte antigen (HLA) class I molecules: (i) dir

143 dissect the link between hyperexpression of human leukocyte antigen (HLA) class I on the islet cells

144 Humanized mice expressing Human Leukocyte Antigen (HLA) class I or II transgenes h

145 its targeted capacity to selectively remove human leukocyte antigen (HLA) class I proteins from dono

146 Human leukocyte antigen (HLA) class I-associated polymor

147 s spectrometric observations of glycosylated human leukocyte antigen (HLA) class I-bound peptides.

148 hese cells, thus enabling their evasion from human leukocyte antigen (HLA) class I-restricted CD8(+)

149 genetic context influences HIV adaptation to human leukocyte antigen (HLA) class I-restricted immune

150 genome that allow it to escape detection by human leukocyte antigen (HLA) class I-restricted immune

151 immunity and revealed previously undetected human leukocyte antigen (HLA) class I-restricted neoanti

152 ression of dominant inhibitory receptors for human leukocyte antigen (HLA) class I.

153 us diseases pathogen resistance is linked to human leukocyte antigen (HLA) class I/II variants and th

154 tin (orexin), is so strongly associated with human leukocyte antigen (HLA) class II HLA-DQA1( *)01:02

155 ecognize peptide antigens, in the context of human leukocyte antigen (HLA) class II molecules (HLA-II

156 curate prediction of antigen presentation by human leukocyte antigen (HLA) class II molecules would b

157 Here, we demonstrate the presence of human leukocyte antigen (HLA) class II-restricted CD8(+)

158 The immunoregulatory human leukocyte antigen (HLA) complex has been linked to

159 bility signal in the class III region of the human leukocyte antigen (HLA) complex in the South Asian

160 omplex (MHC) protein which is encoded by the human leukocyte antigen (HLA) complex.

161 coprotein that are likely to be presented in human leukocyte antigen (HLA) complexes, and discuss the

162 f pretransplant antibodies directed at donor human leukocyte antigen (HLA) donor-specific antibodies

163 The development of human leukocyte antigen (HLA) donor-specific antibody/an

164 Chemokine receptor 5 (CCR5), human leukocyte antigen (HLA) DR isotope, and cluster of

165 ients with ABMR associated with de novo anti-human leukocyte antigen (HLA) DSA.

166 Human leukocyte antigen (HLA) gene variation is associat

167 Variation in the human leukocyte antigen (HLA) genes accounts for one-hal

168 ng been thought to arise from alleles of the human leukocyte antigen (HLA) genes at that locus(3-6).

169 Human leukocyte antigen (HLA) genes confer substantial r

170 tion sequencing (NGS)-based typing of the 33 human leukocyte antigen (HLA) genes in 1,120 individuals

171 he understanding of how variation within the human leukocyte antigen (HLA) genes influences risk of m

172 NA sequencing studies have demonstrated that human leukocyte antigen (HLA) genes may be expressed in

173 st polymorphic genetic system in humans, the human leukocyte antigen (HLA) genes of the adaptive immu

174 IRF7, NOTCH4, PLAUR, CSK, IRAK1, and several human leukocyte antigen (HLA) genes.

175 ell killer immunoglobulin-like receptors and human leukocyte antigen (HLA) genotype with risk of CMV

176 The human leukocyte antigen (HLA) haplotype reference panel

177 the tight association of narcolepsy with the human leukocyte antigen (HLA) HLA-DQB1*06:02 allele, we

178 dies (DSA) directed against mismatched donor human leukocyte antigen (HLA) is a major risk factor for

179 interaction between inhibitory receptors and human leukocyte antigen (HLA) ligands and bound peptide.

180 transplantation consider information at the human leukocyte antigen (HLA) loci.

181 However, loss of heterozygosity at the human leukocyte antigen (HLA) locus and loss of chromoso

182 The human leukocyte antigen (HLA) locus is strongly associat

183 s, several reports linked the disease to the human leukocyte antigen (HLA) locus on chromosome 6, fol

184 The human leukocyte antigen (HLA) locus plays a critical rol

185 g the ability to present neoantigens through human leukocyte antigen (HLA) loss may facilitate immune

186 on the variation of survival with degree of human leukocyte antigen (HLA) mismatch.

187 incidence of AE increased with the number of human leukocyte antigen (HLA) mismatches (18%, 10%, and

188 Then, three decades ago, an unusual human leukocyte antigen (HLA) molecule was identified: H

189 sented on the cell surface in the context of human leukocyte antigen (HLA) molecules have been target

190 receptors (KIRs) with their target ligands, human leukocyte antigen (HLA) molecules, is a critical c

191 restrict ASI to patients expressing specific Human Leukocyte Antigen (HLA) molecules, thus stratifyin

192 des with high-affinity binding of autologous human leukocyte antigen (HLA) molecules.

193 , including the antigen-presenting classical human leukocyte antigen (HLA) molecules.

194 the binding preferences of the best-matched Human Leukocyte Antigen (HLA) pocket for each SLA pocket

195 (IAV) increases the presentation of class I human leukocyte antigen (HLA) proteins that limit antivi

196 f the host, and is linked to their allele of human leukocyte antigen (HLA) proteins, which present pr

197 These include transcripts encoding human leukocyte antigen (HLA) receptors as well as B cel

198 Fine-mapping of the human leukocyte antigen (HLA) region confirms the neurol

199 Genotype imputation of the human leukocyte antigen (HLA) region is a cost-effective

200 Additionally, the human leukocyte antigen (HLA) region was comprehensively

201 lection favoring sub-Saharan ancestry at the human leukocyte antigen (HLA) region, across North Afric

202 geal cancer associations were limited to the human leukocyte antigen (HLA) region, and classical HLA

203 g heritability of IQ might lie hidden in the human leukocyte antigen (HLA) region, which plays a crit

204 rin gene, the C11orf30/LRRC32 locus, and the human leukocyte antigen (HLA) region.

205 ping and imputation was used to fine-map the human leukocyte antigen (HLA) region.

206 wide association studies and SNPs within the human leukocyte antigen (HLA) region.

207 Patterns of human leukocyte antigen (HLA) restriction of immunodomin

208 In addition, human leukocyte antigen (HLA) serotypes were also impute

209 ipient suitability for HSCT is determined by Human Leukocyte Antigen (HLA) similarity.

210 Human leukocyte antigen (HLA) supertypes are groups of f

211 Genes of the human leukocyte antigen (HLA) system encode cell-surface

212 on of high sequence divergence harboring the human leukocyte antigen (HLA) system, we found that loca

213 Moreover, using the human leukocyte antigen (HLA) transgenic rabbit model, w

214 The purpose of this study was to identify human leukocyte antigen (HLA) type as risk and prognosti

215 A implements a new graph alignment model for human leukocyte antigen (HLA) type inference, based on t

216 -8 epitopes for each of the 6 most prevalent human leukocyte antigen (HLA) types.

217 on Workflow Language (CWL) implementation of human leukocyte antigen (HLA) typing using Polysolver or

218 helial in vitro model of ABMR due to class I human leukocyte antigen (HLA) with and without complemen

219 unique peptides associated with the class I human leukocyte antigen (HLA), of which 98 peptides were

220 Aggregate morphologies also influence Human Leukocyte Antigen (HLA)--types recognized by the a

221 een patients with glioblastomas positive for human leukocyte antigen (HLA)-A*02:01 or HLA-A*24:02 wer

222 cells after immune-affinity purification of human leukocyte antigen (HLA)-A2 and bioinformatics to i

223 eactive CD8(+) T cells in situ, in islets of human leukocyte antigen (HLA)-A2(+) donors and isolation

224 uction of genes encoding human cytokines and human leukocyte antigen (HLA)-A2.1 by adeno-associated v

225 es (RA) (n) AAKKKYCL covalently bound to the human leukocyte antigen (HLA)-B*0801.

226 ural variation of the two minimally distinct human leukocyte antigen (HLA)-B*27:05 and HLA-B*27:09 su

227 Expression of human leukocyte antigen (HLA)-B27 is strongly associated

228 Consecutive patients with AU who were human leukocyte antigen (HLA)-B27 positive or HLA-B27 ne

229 Identification of human leukocyte antigen (HLA)-bound peptides by liquid c

230 Human leukocyte antigen (HLA)-C*06:02 is identified as t

231 all studies suggest that the presence of the human leukocyte antigen (HLA)-Cw6 (C*06:02) allele may b

232 The highly homologous human leukocyte antigen (HLA)-DQ2 molecules, HLA-DQ2.5 a

233 Human leukocyte antigen (HLA)-DQ2.5 (DQA1*05/DQB1*02) is

234 es found associations of narcolepsy with the human leukocyte antigen (HLA)-DQ6 allele and T-cell rece

235 h increased expression of maturation markers human leukocyte antigen (HLA)-DR and CD86, enhanced tumo

236 ntified T-cell epitopes presented in vivo by human leukocyte antigen (HLA)-DR molecules in patients'

237 heterozygosity for the previously validated human leukocyte antigen (HLA)-DR*03:01 risk allele predi

238 We evaluated human leukocyte antigen (HLA)-DR/DQ molecular mismatch t

239 studies have reported an association between human leukocyte antigen (HLA)-DRB1 and the risk of PD.

240 Specific alleles of the human leukocyte antigen (HLA)-DRB1 gene (HLA-DRB1) encod

241 onse restricted by the human MHC-Ib molecule human leukocyte antigen (HLA)-E and specific for an epit

242 The banking of human leukocyte antigen (HLA)-homozygous-induced pluripo

243 Human leukocyte antigen (HLA)-independent, T cell-mediat

244 e target virus-derived peptides presented by human leukocyte antigen (HLA).

245 Antibodies targeting human leukocyte antigen (HLA)/major histocompatibility c

246 of antinuclear antibodies (ANA), presence of human leukocyte antigen (HLA-)B27, age of onset of JIA,

247 -1 gB, gD, VP11/12, and VP13/14 proteins, in human leukocyte antigen (HLA-A*0201) transgenic rabbits

248 ole attributed to the genes encoding class I human leukocyte antigens (HLA) and the chemokine recepto

249 atic determinants that underlie targeting of human leukocyte antigens (HLA) by anti-HLA alloantibodie

250 ta (alleles, genes or haplotypes) related to human leukocyte antigens (HLA), killer-cell immunoglobul

251 hods developed for other complex loci (e.g., human leukocyte antigen [HLA]) on the basis of SNP data

252 ctivated and mobilized within immunodominant human-leukocyte-antigen-(HLA)-A*11:01-restricted CD8(+)

253 Understanding the binding between human leukocyte antigens (HLAs) and peptides is importan

254 Interactions between human leukocyte antigens (HLAs) and peptides play a crit

255 viral evasion of innate immunity.IMPORTANCE Human leukocyte antigens (HLAs) are cell surface protein

256 tocompatibility complex (MHC), which encodes human leukocyte antigens (HLAs) in humans.

257 The peptides dissociate from the class I human leukocyte antigens (HLAs) upon acid denaturation.

258 region harboring genes encoding the class II human leukocyte antigens (HLAs): rs557011[T] (minor alle

259 ay of similar epitopes presented by the same human leukocyte antigen II (HLA-II) molecule.

260 report on a safe conversion to belatacept in human leukocyte antigen-immunized patients with low DSA

261 ted conversion from CNIs to belatacept in 29 human leukocyte antigen-immunized renal-transplant recip

262 ) for SCCHN risk highlight the importance of human leukocyte antigen loci for oropharyngeal cancer ri

263 Genetic variation across the human leukocyte antigen loci is known to influence renal

264 , the impact of genetic variation beyond the human leukocyte antigen loci is less clear.

265 associations to genetic variants, including human leukocyte antigen loci with carbamazepine-induced

266 c hypomethylation of the region encoding the human leukocyte antigen locus (HLA).

267 nnective tissue disorder associated with the human leukocyte antigen locus.

268 ease susceptibility has been associated with human leukocyte antigen locus.

269 Here, we present loss of heterozygosity in human leukocyte antigen (LOHHLA), a computational tool t

270 two defined pre-transplant characteristics: human leukocyte antigen match (10/10 versus <10/10) and

271 ge to the recipient (younger donor or better human leukocyte antigen match), whereas delays beyond 3

272 T), whereas others may not have a compatible human leukocyte antigen-matched donor.

273 hese were compared to CD4(+) responses in 10 human leukocyte antigen-matched persons with HCV spontan

274 ntation of hematopoietic stem cells from his human leukocyte antigen-matched sister 1 year prior to a

275 ntation of hematopoietic stem cells from his human leukocyte antigen-matched sister 1 year prior to a

276 ogenously and capable of recognizing cognate human leukocyte antigen-matched tumors are emerging as r

277 ed to transplantation at age 49 with a 12/12 human leukocyte antigen-matched unrelated donor.

278 Human leukocyte antigen mismatch number (hazards ratio,

279 y prior T-cell-mediated rejection and BKVAN, human leukocyte antigen mismatch, cyclosporine therapy,

280 raoperative blood transfusions, reoperation, human leukocyte antigen mismatch, use of nonstandard imm

281 ATG) to mixed lymphocyte co-cultures between human leukocyte antigen-mismatched peripheral blood lymp

282 0.002) in the adjusted models independent of human leukocyte antigen mismatches and initial immunosup

283 age, basiliximab induction, sex, donor age, human leukocyte antigen mismatches, human leukocyte anti

284 We show that both alleles of genes encoding human leukocyte antigen molecules and genes encoding com

285 iting, with either loss of heterozygosity in human leukocyte antigens or depletion of expressed neoan

286 gets presented as peptides in the context of human leukocyte antigen (peptide-human leukocyte antigen

287 T cell receptor (TCR) recognition of peptide-human leukocyte antigen (pHLA) complexes and is essentia

288 We used yeast-display libraries of peptide-human leukocyte antigen (pHLA) to screen for antigens of

289 nd activated C3 localized at synapses within human leukocyte antigen-positive cell processes and lyso

290 tide polymorphism rs41269979 in the class II human leukocyte antigen region was more frequent in the

291 ping analysis to dissect associations in the human leukocyte antigen region, which suggests important

292 c antigen receptor, enabling this simple non-human leukocyte antigen-restricted approach to enhanced

293 nical characteristics, the identification of human leukocyte antigen risk alleles, and drug-induced p

294 age, rank of transplantation, and absence of human leukocyte antigen sensitization.

295 clonotypes were detected among patients with human leukocyte antigen susceptibility alleles.

296 s of microproteins that are presented by the human leukocyte antigen system.

297 ometry and a highly multiplexed peptide-HLA (human leukocyte antigen) tetramer staining strategy, we

298 and ALD (n = 10) patients, alongside genomic human leukocyte antigen typing.

299 e human tumor antigen NY-ESO-1 (ESO) and the human leukocyte antigen variant HLA-A*0201 (A2) as a mod

300 which creates a neoepitope presented by the human leukocyte antigen with the A2 serotype (HLA-A2) th